BioCardia, Inc. (NasdaqCM: BCDA)
Health Care · Biotechnology · US
$0.92
-11.53% today · -36.5% 1Y
BioCardia, Inc. (NasdaqCM: BCDA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.93M and employs 17 people.
Over the last twelve months the share price has lost 36.5%, trading between 0.75 and 1.80.
Tweenvest scores BioCardia, Inc. across four factors: quality 33/100, value 46/100. Its strongest factor is value.
BCDA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.93M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.74
- Dividend yield
- —
- Beta (5Y)
- 0.62
- 52-week high
- $1.80
- 52-week low
- $0.75
- Avg volume (3M)
- —
- Shares outstanding
- 15.14M
- Employees
- 17
- Next earnings
- —
About BioCardia, Inc.
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
- ISIN
- US09060U6064
- Listed since
- Nov 13, 1996
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Allarity Therapeutics, Inc.NasdaqCM: ALLR | $14.24M | $0.90 | -9.60% |
| Abera Bioscience ABNGM: ABERA | $14.09M | Skr— | — |
| Pasithea Therapeutics Corp.NasdaqCM: KTTA | $14.03M | $0.42 | -10.16% |
| Xintela AB (publ)OM: XINT | $14.00M | Skr0.16 | -10.31% |
| Biophytis S.A.ENXTPA: ALBPS | $13.57M | €0.03 | +8.81% |
| Genflow Biosciences plcLSE: GENF | $13.22M | £0.02 | -1.41% |
| Alzinova AB (publ)OM: ALZ | $13.21M | Skr0.43 | -1.96% |
| Genomed Spólka AkcyjnaWSE: GEN | $13.14M | zł38.60 | -3.50% |
Figures last refreshed Oct 18, 2026.